Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 12/20 | 0.49 |
| ▸ | GRM1 | Q13255 | 5/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3381165 | 0.88 | POLB (0.40) | F10GRM1PTGS2SMN1; SMN2 | |
| SCHEMBL3377194 | 0.85 | F10 (0.41) | F10GRM1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3380128 | 0.85 | F10 (0.54) | F10GRM1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3376468 | 0.85 | AHR (0.40) | F10GRM1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3378168 | 0.84 | F10 (0.63) | F10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3379883 | 0.80 | F10 (0.47) | F10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3614270 | 0.78 | PRSS12 (0.44) | F10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3611444 | 0.77 | NPC1 (0.41) | F10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3619322 | 0.76 | FLT1 (0.42) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL1022331 | 0.75 | F10 (0.71) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029586-B1 | ISOINDOLIN-1-ONE-, ISOINDOLIN-3-ONE- AND ISOINDOLIN-1,3-DIONE-DERIVATIVES AND USE THEREOF | BAYER SCHERING PHARMA AG (DE) | 2010-11-24 | — | — | EP | disclosed |
| US-20100010060-A1 | Isoindolin-1-One-, Isoindolin-3-One- and Isoindolin-1,3-Dione-Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2010-01-14 | — | — | US | disclosed |
| US-20100010060-A1 | Isoindolin-1-One-, Isoindolin-3-One- and Isoindolin-1,3-Dione-Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2010-01-14 | — | — | US | disclosed |
| EP-2029586-A1 | ISOINDOLIN-1-ONE-, ISOINDOLIN-3-ONE- AND ISOINDOLIN-1,3-DIONE-DERIVATIVES AND USE THEREOF | Bayer HealthCare AG (DE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007137800-A1 | ISOINDOLIN-1-ONE-, ISOINDOLIN-3-ONE- AND ISOINDOLIN-1,3-DIONE-DERIVATIVES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010060-A1 | Isoindolin-1-One-, Isoindolin-3-One- and Isoindolin-1,3-Dione-Derivatives and Use Thereof | ICAM1, SERPINC1, TFPI2 | F10 264/4885GRM1 3235/4885PTGS2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.